Intestinal absorption of penclomedine from lipid vehicles in the conscious rat: Contribution of emulsification versus digestibility

International Journal of Pharmaceutics

Volumn 270, Issue 1-2, 2004, Pages 109-118

  De Smidt, P Chris ^a,b   Campanero, Miguel A ^a   Trocóniz, Iñaki F ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Parnassia Research Centre   (Netherlands)

Author keywords

Bioavailability; Emulsion; Lipolysis; Medium chain triglycerides; Penclomedine; Pharmacokinetics; Tocophersolan (TPGS)

Indexed keywords

DRUG VEHICLE; LIPID EMULSION; MEDIUM CHAIN TRIACYLGLYCEROL; MIGLYOL; PENCLOMEDINE; TETRAHYDROLIPSTATIN; TOCOFERSOLAN;

ARTICLE; CONSCIOUSNESS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EMULSION; INTESTINE ABSORPTION; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT;

EID: 0347022226     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2003.10.036     Document Type: Article

References (35)

1. Beal, S., Sheiner, L., 1992. NONMEM Users Guides. NONMEM project group, University of California, San Francisco.
2. Beal, S., Sheiner, L., 1999. Intermediate level workshop in population pharmacokinetic data analysing using the NONMEM system. Uppsala, Sweden.
3. Bloedow D., Hayton W. Effects of lipids on bioavailability of sulfisoxazole acetyl, dicumarol, and griseofulvin in rats. J. Pharm. Sci. 65:1976;328-334.
4. Borgstrom B. Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim. Biophys. Acta. 962:1988;308-316.
5. Carey M.C., Small D.M., Bliss C.M. Lipid digestion and absorption. Annu. Rev. Physiol. 45:1983;651-677.
6. Charman S.A., Charman W.N., Rogge M.C., Wilson T.D., Dutko F.J., Pouton C.W. Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm. Res. 9:1992;87-93.
7. Charman W. Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J. Pharm. Sci. 89:2000;967-978.
8. Charman W.N., Porter C.J., Mithani S., Dressman J.B. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J. Pharm. Sci. 86:1997;269-282.
9. Fernandez E., Borgstrom B. Effects of tetrahydrolipstatin, a lipase inhibitor, on absorption of fat from the intestine of the rat. Biochim. Biophys. Acta. 1001:1989;249-255.
10. Gershanik T., Benita S. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur. J. Pharm. Biopharm. 50:2000;179-188.
11. Grundy D. The effect of surgical anaesthesia on antral motility in the ferret. Exp. Physiol. 75:1990;701-708.
12. Hadváry P., Lengsfeld H., Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem. J. 256:1988;357-361.
13. Healy T., Foster G., Evans D., Syed A. Effect of some i.v. anaesthetic agents on canine gastrointestinal motility. Br. J. Anaesth. 53:1981;229-233.
14. Hernell O., Staggers J., Carey M. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. Biochemistry. 29:1990;2041-2056.
15. Humberstone A., Charman W. Lipid-based vehicles for the oral delivery of poorly water-soluble drugs. Adv. Drug Deliv. Rev. 25:1997;103-128.
16. Iwanaga, K., Kushibiki, T., Kawabata, Y., Miyazaki, M., Kakemi, M., Yamashita, S., 2000. Mechanisms of intestinal absorption of water-insoluble drugs from lipid-based formulations. In: Proceedings of the Millennial World Congress of Pharmaceutical Sciences, International Pharmaceutical Federation, San Francisco, p. 109.
17. Liu G., Berlin J., Tutsch K., van Ummersen L., Dresen A., Marnocha R., Arzomanian R., Alberti D., Feierabend C., Binger K., Wilding G. Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy. Clin. Cancer Res. 8:2002;706-711.
18. MacGregor K.J., Embleton J.K., Lacy J.E., Perry E.A., Solomon L.J., Seager H., Pouton C.W. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv. Drug Deliv. Rev. 25:1997;33-46.
19. Myers R., Stella V. Systemic bioavailability of penclomedine (NSC-338720) from oil-in-water emulsions administered intraduodenally in rats. Int. J. Pharm. 78:1992;217-226.
20. Nankervis R., Davis S., Day N., Shaw P. Intestinal lymphatic transport of three retinoids in the rat after oral administration: effect of lipophilicity and lipid vehicle. Int. J. Pharm. 130:1996;57-64.
21. O'Reilly S., Hartman N., Bowling K., Rowinsky E., Donehower R., Collins J., Strong J. Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine. Cancer Chemother. Pharmacol. 48:2001;223-228.
22. Palin K., Wilson C., Davis S., Phillips A. The effect of oils on the lymphatic absorption of DDT. J. Pharm. Pharmacol. 34:1982;707-710.
23. Patton, J., Vetter, R., Hamosh, M., Borgstrom, B., Lindstrom, M., Carey, M., 1985. The light microscopy of lipid digestion. Food Microstructure, 29-41.
24. Porter C., Charman W. In vitro assessment of oral lipid based formulations. Adv. Drug Deliv. Rev. 1:2001;S127-S147.
25. Prankerd R., Frank S., Stella V. Preliminary development and evaluation of a parenteral emulsion formulation of penclomedine (NSC-338720; 3,5-dichloro-2,4-dimethoxy-6-trichloromethylpyridine): a novel, practically water insoluble cytotoxic agent. J. Parenter. Sci. Technol. 42:1988;76-81.
26. Rautureau M., Rambaud J. Aqueous solubilization of vitamin D3 in normal man. Gut. 122:1981;76-81.
27. Reymond J.-P., Sucker H., Vonderscher J. In vivo model for ciclosporin intestinal absorption in lipid vehicles. Pharm. Res. 5:1988;677-679.
28. Rowland, M., Tozer, T., 1995. Clinical Pharmacokinetics: Concepts and Applications, 3rd ed. Lea & Febiger, Williams & Wilkins, Philadelphia, USA, Chapter 4, pp. 38-39, Chapter 19, p. 318.
29. Sheiner L., Grasela T. An introduction to mixed effect modeling: concepts, definitions, and justification. J. Pharmacokinet. Biopharm. 19:1991a;11S-24S.
30. Sheiner L., Grasela T. Pharmacostatistical modelling for observational data. J. Pharmacokinet. Biopharm. 19:1991b;25S-36S.
31. Staggers J., Hernell O., Stafford R., Carey M. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 1. Phase behavior and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings. Biochemistry. 29:1990;2028-2040.
32. Vetter R., Carey M., Patton J. Coassimilation of dietary fat and benzo(a)pyrene in the small intestine: an absorption model using the killifish. J. Lipid Res. 26:1985;428-434.
33. Wieboldt R., Campbell D., Henion J. Quantitative liquid chromatographic-tandem mass spectrometric determination of orlistat in plasma with a quadrupole ion trap. J. Chromatogr. B: Biomed. Sci. Appl. 708:1998;121-129.
34. Yamahira Y., Noguchi T., Takenaka H., Maeda T. Biopharmaceutical studies of lipid-containing oral dosage forms: relationship between drug absorption rate and digestibility of vehicles. Int. J. Pharm. 3:1979;23-31.
35. Yu L., Bridgers A., Polli J., Vickers A., Long S., Roy A., Winnike R., Coffin M. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm. Res. 16:1999;1812-1817.